Alzinova AB (publ) announced that the company has received approval from the regulatory authorities in Finland to initiate the first clinical study with the vaccine candidate, ALZ-101. The Phase 1b clinical study with ALZ-101 in Alzheimer's patients will evaluate the vaccine candidate's tolerability and safety. It will also study the immunological response to the vaccine after multiple doses, as well as a number of biomarkers that are associated with Alzheimer's disease. The study will be carried out in collaboration with Alzinova's partner, Clinical Research Services Turku (CRST), in Finland who have extensive experience in Alzheimer's studies and the biomarker work will be done in the context of a research collaboration together with Sahlgrenska University Hospital in Gothenburg. Ethical approval is already in place, and the first patient in the study will be recruited shortly. Amyloid-beta is considered to be a key factor in the development of Alzheimer's disease, and in particular, the soluble oligomeric forms of amyloid-beta appear to be harmful. These are specifically targeted by the ALZ-101 vaccine.